Icon

Adagio Therapeutics Inc Stock Analysis and Price Target COMMON STOCK | Biotechnology | NYE

N/A

Average User
Rating

N/A

Average Analyst
Rating

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis

USD 3.48

0.00 (0.00)%

USD 0.50B

0.27M

N/A

N/A

Icon

ADGI

Adagio Therapeutics Inc (USD)
COMMON STOCK | NYE
USD 3.48
0.00 0

N/A

Average User
Rating

N/A

Average Analyst
Rating

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis

USD 0.50B

N/A

USD 3.48

Adagio Therapeutics Inc Stock Forecast

N/A

Based on the Adagio Therapeutics Inc stock forecasts from 0 analysts, the average analyst target price for Adagio Therapeutics Inc is not available over the next 12 months. Adagio Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Adagio Therapeutics Inc is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, Adagio Therapeutics Inc’s stock price was USD 3.48. Adagio Therapeutics Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -12.12% over the last year.

No recent analyst target price found for Adagio Therapeutics Inc
No recent average analyst rating found for Adagio Therapeutics Inc

Company Overview

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutra...Read More

https://adagiotx.com

1601 Trapelo Road, Waltham, MA, United States, 02451

101

December

USD

USA

Adjusted Closing Price

Loading...

Technical Indicators

Unadjusted Closing Price

Loading...

Assets

Top Holdings

Top Sectors

Top Regions

Share Volume

Loading...

Relative Performance

Symbol Capital Gain Dividend Return Total Return
Loading...

Stocks Similar To Adagio Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN
Regeneron Pharmaceuticals Inc 0.00 (0.00%) USD82.14B 19.35 12.07

ETFs Containing ADGI

Symbol Name Weight Mer Price(Change) Market Cap
no data

Frequently Asked Questions About ADGI Stock

Stock Target Advisor's fundamental analysis for Adagio Therapeutics Inc's stock is Slightly Bearish.

Unfortunately we do not have enough data on ADGI's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on ADGI's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on ADGI's stock to indicate if its overvalued.

The last closing price of ADGI's stock was USD 3.48.

The most recent market capitalization for ADGI is USD 0.50B.

Unfortunately we do not have enough analyst data on ADGI's stock to indicate whether its price will go up or not.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...